Cargando…

Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study

Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It is also associated with loss of muscle mass and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Braga-Basaria, Milena, Travison, Thomas G., Taplin, Mary-Ellen, Lin, Alexander, Dufour, Alyssa B., Habtemariam, Daniel, Nguyen, Paul L., Kibel, Adam S., Ravi, Praful, Bearup, Richelle, Kackley, Hannah, Kafel, Hussein, Reid, Kieran, Storer, Thomas, Simonson, Donald C., McDonnell, Marie, Basaria, Shehzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916640/
https://www.ncbi.nlm.nih.gov/pubmed/36763576
http://dx.doi.org/10.1371/journal.pone.0281508
_version_ 1784886175271485440
author Braga-Basaria, Milena
Travison, Thomas G.
Taplin, Mary-Ellen
Lin, Alexander
Dufour, Alyssa B.
Habtemariam, Daniel
Nguyen, Paul L.
Kibel, Adam S.
Ravi, Praful
Bearup, Richelle
Kackley, Hannah
Kafel, Hussein
Reid, Kieran
Storer, Thomas
Simonson, Donald C.
McDonnell, Marie
Basaria, Shehzad
author_facet Braga-Basaria, Milena
Travison, Thomas G.
Taplin, Mary-Ellen
Lin, Alexander
Dufour, Alyssa B.
Habtemariam, Daniel
Nguyen, Paul L.
Kibel, Adam S.
Ravi, Praful
Bearup, Richelle
Kackley, Hannah
Kafel, Hussein
Reid, Kieran
Storer, Thomas
Simonson, Donald C.
McDonnell, Marie
Basaria, Shehzad
author_sort Braga-Basaria, Milena
collection PubMed
description Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It is also associated with loss of muscle mass and increased adiposity. This change in body composition is likely the inciting event in the development of insulin resistance, an independent risk factor for diabetes mellitus and cardiovascular disease. Although the occurrence of insulin resistance during ADT has been reported, it remains unclear whether this insulin resistance is primarily hepatic or muscular. Similarly, the mechanisms that lead to insulin resistance also remain unknown. The ADT & Metabolism Study was designed to address these knowledge gaps, as the elucidation of the predominant site of insulin resistance will allow prevention strategies and the use of targeted, tissue-specific insulin-sensitizing agents in patients undergoing ADT. This prospective, mechanistic, single-center, 24-week, observational cohort study will enroll treatment-naïve adult men with prostate cancer about to undergo surgical or medical ADT for at least 24 weeks (ADT group; n = 50) and a control group of men who had undergone radical prostatectomy and are in remission (non-ADT group, n = 25). The primary outcome is to determine the site of insulin resistance (skeletal muscle or liver) using frequent sampling oral glucose tolerance test at baseline and 12 and 24 weeks after commencement of ADT (ADT group) or after enrollment in the study (non-ADT group). Secondary outcomes will assess changes in hepatic and intramyocellular fat (using magnetic resonance spectroscopy), inflammatory markers, adipokines, free fatty acids, and changes in body composition (assessed using dual-energy x-ray absorptiometry) and their correlation with the development of insulin resistance. Exploratory outcomes will include changes in muscle performance, physical function, physical activity, vitality, and sexual drive.
format Online
Article
Text
id pubmed-9916640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-99166402023-02-11 Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study Braga-Basaria, Milena Travison, Thomas G. Taplin, Mary-Ellen Lin, Alexander Dufour, Alyssa B. Habtemariam, Daniel Nguyen, Paul L. Kibel, Adam S. Ravi, Praful Bearup, Richelle Kackley, Hannah Kafel, Hussein Reid, Kieran Storer, Thomas Simonson, Donald C. McDonnell, Marie Basaria, Shehzad PLoS One Study Protocol Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It is also associated with loss of muscle mass and increased adiposity. This change in body composition is likely the inciting event in the development of insulin resistance, an independent risk factor for diabetes mellitus and cardiovascular disease. Although the occurrence of insulin resistance during ADT has been reported, it remains unclear whether this insulin resistance is primarily hepatic or muscular. Similarly, the mechanisms that lead to insulin resistance also remain unknown. The ADT & Metabolism Study was designed to address these knowledge gaps, as the elucidation of the predominant site of insulin resistance will allow prevention strategies and the use of targeted, tissue-specific insulin-sensitizing agents in patients undergoing ADT. This prospective, mechanistic, single-center, 24-week, observational cohort study will enroll treatment-naïve adult men with prostate cancer about to undergo surgical or medical ADT for at least 24 weeks (ADT group; n = 50) and a control group of men who had undergone radical prostatectomy and are in remission (non-ADT group, n = 25). The primary outcome is to determine the site of insulin resistance (skeletal muscle or liver) using frequent sampling oral glucose tolerance test at baseline and 12 and 24 weeks after commencement of ADT (ADT group) or after enrollment in the study (non-ADT group). Secondary outcomes will assess changes in hepatic and intramyocellular fat (using magnetic resonance spectroscopy), inflammatory markers, adipokines, free fatty acids, and changes in body composition (assessed using dual-energy x-ray absorptiometry) and their correlation with the development of insulin resistance. Exploratory outcomes will include changes in muscle performance, physical function, physical activity, vitality, and sexual drive. Public Library of Science 2023-02-10 /pmc/articles/PMC9916640/ /pubmed/36763576 http://dx.doi.org/10.1371/journal.pone.0281508 Text en © 2023 Braga-Basaria et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Study Protocol
Braga-Basaria, Milena
Travison, Thomas G.
Taplin, Mary-Ellen
Lin, Alexander
Dufour, Alyssa B.
Habtemariam, Daniel
Nguyen, Paul L.
Kibel, Adam S.
Ravi, Praful
Bearup, Richelle
Kackley, Hannah
Kafel, Hussein
Reid, Kieran
Storer, Thomas
Simonson, Donald C.
McDonnell, Marie
Basaria, Shehzad
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title_full Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title_fullStr Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title_full_unstemmed Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title_short Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
title_sort gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the adt & metabolism study): protocol of a longitudinal, observational, cohort study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916640/
https://www.ncbi.nlm.nih.gov/pubmed/36763576
http://dx.doi.org/10.1371/journal.pone.0281508
work_keys_str_mv AT bragabasariamilena gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT travisonthomasg gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT taplinmaryellen gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT linalexander gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT dufouralyssab gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT habtemariamdaniel gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT nguyenpaull gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT kibeladams gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT ravipraful gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT bearuprichelle gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT kackleyhannah gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT kafelhussein gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT reidkieran gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT storerthomas gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT simonsondonaldc gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT mcdonnellmarie gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy
AT basariashehzad gainingmetabolicinsightinoldermenundergoingandrogendeprivationtherapyforprostatecancertheadtmetabolismstudyprotocolofalongitudinalobservationalcohortstudy